Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $9.62 million versus the consensus estimate of $16.23 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.